Celecoxib; Tramadol Hydrochloride Patent Expiration
Celecoxib; Tramadol Hydrochloride is Used for managing pain in adults. It was first introduced by Kowa Pharmaceuticals America Inc
Celecoxib; Tramadol Hydrochloride Patents
Given below is the list of patents protecting Celecoxib; Tramadol Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Seglentis | US8846744 | Pharmaceutical compositions of co-crystals of tramadol and coxibs | Jun 03, 2031 | Kowa Pharms |
| Seglentis | US10238668 | Co-crystals of tramadol and coxibis | Apr 19, 2030 | Kowa Pharms |
| Seglentis | US10245276 | Co-crystals of tramadol and coxibs | Apr 19, 2030 | Kowa Pharms |
| Seglentis | US10548909 | Co-crystals of tramadol and coxibs | Apr 19, 2030 | Kowa Pharms |
| Seglentis | US11478488 | Co-crystals of tramadol and coxibs | Apr 19, 2030 | Kowa Pharms |
| Seglentis | US8598152 | Co-crystals of tramadol and coxibs | Apr 19, 2030 | Kowa Pharms |
| Seglentis | US9012440 | Co-crystals of tramadol and coxibs | Apr 19, 2030 | Kowa Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Celecoxib; Tramadol Hydrochloride's patents.
Latest Legal Activities on Celecoxib; Tramadol Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Celecoxib; Tramadol Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US10238668 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US8598152 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US9012440 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US10548909 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US8846744 |
| Notice of Final Determination- Ineligible | 06 Jun, 2024 | US10245276 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10238668 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10245276 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10548909 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US8598152 |
Celecoxib; Tramadol Hydrochloride's Family Patents
